Nasdaq · Healthcare
Vanda Pharmaceuticals Inc. (VNDA)
As-reported financials and recent SEC filings for Vanda Pharmaceuticals Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$216.1M
Net income
$-220.5M
Net margin
-102.0%
Diluted EPS
$-3.74
ROE
-67.4%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $216.1M | $198.8M | $192.6M | $254.4M | $268.7M |
| Gross profit | — | — | — | — | — |
| Operating income | $-151.2M | $-40.7M | $-14.0M | $6.3M | $42.2M |
| Net income | $-220.5M | $-18.9M | $2.5M | $6.3M | $33.2M |
| Diluted EPS | $-3.74 | $-0.33 | $0.04 | $0.11 | $0.58 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-08
View on EDGAR →42026-06-08
View on EDGAR →42026-06-08
View on EDGAR →42026-06-08
View on EDGAR →42026-06-08
View on EDGAR →42026-06-08
View on EDGAR →42026-06-08
View on EDGAR →32026-06-08
View on EDGAR →Largest Healthcare peers
Go deeper on VNDA
Search Vanda Pharmaceuticals Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.